StockData

Pulmonx vs TELA Bio

LUNG and TELA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LUNG and TELA compare

Pulmonx is the larger company, worth 3.4 times as much as TELA Bio ($117M against $34.2M).

TELA Bio grew revenue faster over the last twelve months (6.1% versus −3.4% for Pulmonx).

TELA Bio keeps more of each dollar of sales as profit, with a net margin of −51.5% compared with −55.0% at Pulmonx.

Pulmonx scores higher on the StockData Score (7 against 5 for TELA Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLUNGTELA
Size and price
Market cap$117M$34.2M
Share price$2.73$0.762
Change, 1 year83.6%−23.7%
Change, 5 years−91.9%−93.8%
Beta (5Y)2.512.04
Employees296218
StockData Score
Total score7 (better)5
Valuation score3 (better)1
Growth score22
Performance score11
Health score11
Dividend score00
Valuation
P/S1.3×0.4× (better)
P/B3.0×–
FCF yield−26.1% (better)−92.4%
Fair value$4.87–
Margin of safety43.8%–
Growth
Revenue growth (TTM)−3.4%6.1% (better)
Revenue growth, 5Y average22.6%34.5% (better)
Profitability
Gross margin77.1% (better)67.8%
Operating margin−53.0%−42.6% (better)
Net margin−55.0%−51.5% (better)
FCF margin−35.1% (better)−39.6%
Return on equity−88.9%–
Return on invested capital−142% (better)−212%
Financial health
Debt / equity0.96–
Interest coverage−12.3×−4.9× (better)
Current ratio4.32 (better)2.99
Altman Z-score−5.58 (better)−9.41
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions61.0%70.5%
Held by insiders16.6%41.0%
Insider net buying, 12 months−$548K$186K (better)
Short interest, % of float2.2%2.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.